Replicor to disclose interim REP 2055 clinical efficacy data in patients with chronic hepatitis B at the 61st annual meeting of the AASLD in Boston, U.S.A.
October 28, 2010 – Replicor will disclose updated interim results from its proof of concept clinical trial at the 61st annual meeting of the American Association for the Study of Liver Disease (AASLD) APASL in Boston, U.S.A. (currently being held from Oct 28 – Nov 2). This is the largest annual meeting dedicated to treatment of liver disease which typically attracts over 8,000 physicians and researchers. This trial is examining the safety and efficacy of REP 2055 in human patients with chronic hepatitis B (HBV).
REP 2055 represents a new class of antiviral agent that blocks the release of hepatitis B surface antigen (HBsAg) which has been associated with HBV-specific immune defects and may contribute to the long term persistence of HBV infection in the liver. REP 2055 has previously been shown to rapidly clear HBsAg in the serum of patients infected with HBV and appears to allow these patients to regain effective immunological control over their infection, resulting in sustained virologic responses after only 5-6 months of treatment. Replicor will present updated clinical efficacy results from an expanded population of patients in a poster presentation on Saturday Oct 30, 2010.